New Test May Detect More Prostate Tumors

A blood test under development may detect more prostate tumors than the current test, and could eliminate thousands of unneeded biopsies, reports the Washington Post. The test, EPCA-2, is being developed by Oconome, Inc. (Seattle) and a research team at Johns Hopkins University (Baltimore). The current test, PSA, produces a lot of false positives, and 80% of the biopsies that result from it come back negative.

April 26, 2007

1 Min Read
New Test May Detect More Prostate Tumors

A study published yesterday in the journal Urology suggests that EPCA-2 is better than PSA at finding real positives and avoiding false positives.For those who are keeping score about when the media cites device companies when there is a medical breakthrough, the Post piece does give credit to Oconome, but not until the eighth paragraph.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like